A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
Award amount
$224,999Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- CUMBERLAND PHARMACEUTICALS, INC.
- Proposal award date
- 2016-09-01
- Contract end date
- 2018-08-31
- UEI
- M2ZXA6LYJ3S5
- Solicitation number
- PA15-270
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Targeting DNA damage response pathways for the treatment of advanced lung cancer
- Targeting DNA damage response pathways for the treatment of advanced lung cancer
- Preclinical Development of a New Drug for Treating Anemia of Chronic Inflammation
- Mannan, A Potential Therapeutic for Asthma
- Radioprotection by use of Topical Lithium Formulations
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
8 SBIR/STTR records share this UEI (2004–2018). Reported award amounts total $3,783,318. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services